Insider trading

Period: 120 months Stock: REGN Minimum amount: $10M × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

48 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

48 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

48 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

48 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
48 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
48 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

48 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
15 Aug 2024
POON CHRISTINE A Director
Sold at will 7×
$12.55M 10,838 at 1,158.17
83.3%
Sold half or more
12 Jun 2024
SCHLEIFER LEONARD S Bd. Co-Chair, President & CEO · indirect
Sold on a plan 3×
$16.41M 16,149 at 1,015.94
100%
Sold half or more
17 May 2024
SCHLEIFER LEONARD S Bd. Co-Chair, President & CEO
Sold on a plan 2×
$22.36M 22,830 at 979.23
4.7%
Planned (10b5-1)
16 May 2024
YANCOPOULOS GEORGE Bd. Co-Chair, President & CSO
Sold on a plan 12×
$48.64M 50,000 at 972.73
6.0%
Planned (10b5-1)
15 May 2024
YANCOPOULOS GEORGE Bd. Co-Chair, President & CSO
Sold on a plan 25×
$48.79M 50,000 at 975.87
5.6%
Planned (10b5-1)
15 May 2024
SCHLEIFER LEONARD S Bd. Co-Chair, President & CEO
Sold on a plan 10×
$10.73M 10,941 at 980.34
2.7%
Planned (10b5-1)
14 May 2024
SCHLEIFER LEONARD S Bd. Co-Chair, President & CEO
Sold on a plan 2×
$24.48M 25,000 at 979.25
5.8%
Planned (10b5-1)
2 Jan 2024
YANCOPOULOS GEORGE Bd. Co-Chair, President & CSO · indirect
Sold on a plan 2×
$30.33M 33,696 at 900.00
15.8%
Planned (10b5-1)
23 Aug 2023
POON CHRISTINE A Director
Sold at will 5×
$10.31M 12,280 at 839.97
85.8%
Sold half or more
6 Feb 2023
YANCOPOULOS GEORGE President and Chief Scientific · indirect
Sold, plan not stated
$10.55M 13,189 at 800.08
6.2%
5 Aug 2022
STAHL NEIL EVP Research and Development
Sold, plan not stated 16×
$14.57M 23,782 at 612.61
31.1%
30 Mar 2022
VAGELOS P ROY Director · indirect
Sold, plan not stated 2×
$20.00M 28,572 at 700.01
54.9%
Sold half or more
27 Aug 2021
POON CHRISTINE A Director
Sold, plan not stated 11×
$10.02M 15,000 at 668.09
89.9%
Sold half or more
18 Aug 2021
SCHLEIFER LEONARD S President & CEO
Sold, plan not stated
$130.01M 200,000 at 650.03
39.6%
16 Aug 2021
YANCOPOULOS GEORGE President and Chief Scientific
Sold, plan not stated 2×
$30.78M 49,227 at 625.29
5.3%
5 Aug 2021
YANCOPOULOS GEORGE President and Chief Scientific
Sold, plan not stated
$30.00M 50,000 at 600.06
5.1%
21 Jun 2021
YANCOPOULOS GEORGE President and Chief Scientific · indirect
Sold, plan not stated 12×
$43.11M 80,000 at 538.90
97.4%
Sold half or more
28 Aug 2020
POON CHRISTINE A Director
Sold, plan not stated 6×
$24.05M 40,000 at 601.22
96.5%
Sold half or more
25 Aug 2020
SING GEORGE L Director
Sold, plan not stated 15×
$19.89M 32,750 at 607.28
33.7%
25 Aug 2020
Van Plew Daniel P EVP & General Mgr Industrial O
Sold, plan not stated 6×
$16.56M 27,109 at 610.89
57.5%
Sold half or more
24 Aug 2020
SING GEORGE L Director
Sold, plan not stated 12×
$11.89M 20,037 at 593.63
19.2%
21 Aug 2020
SING GEORGE L Director
Sold, plan not stated 4×
$12.08M 19,963 at 605.12
17.5%
20 Aug 2020
SING GEORGE L Director
Sold, plan not stated 10×
$12.96M 21,000 at 616.91
16.7%
11 Aug 2020
VAGELOS P ROY Director · indirect
Sold, plan not stated 13×
$20.17M 33,460 at 602.94
40.0%
9 Jun 2020
Sanofi 10% owner · indirect
Sold, plan not stated
$71.84M 120,234 at 597.48
30.1%
29 May 2020
Sanofi 10% owner
Sold, plan not stated
$10.41B 20,421,899 at 509.85
100%
Sold half or more
29 May 2020
Sanofi 10% owner · indirect
Sold, plan not stated
$1.22B 2,399,552 at 509.85
85.7%
Sold half or more
21 May 2020
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 23×
$84.44M 149,594 at 564.44
32.7%
12 May 2020
SCHLEIFER LEONARD S President & CEO
Sold, plan not stated 21×
$85.91M 150,922 at 569.22
24.1%
7 May 2020
Van Plew Daniel P EVP & General Mgr Industrial O
Sold, plan not stated 14×
$22.34M 39,583 at 564.32
58.4%
Sold half or more
6 May 2020
RYAN ARTHUR F Director
Sold, plan not stated 17×
$27.61M 50,124 at 550.88
63.5%
Sold half or more
10 Mar 2020
YANCOPOULOS GEORGE President and Chief Scientific
Sold, plan not stated 25×
$55.43M 117,815 at 470.47
18.5%
9 Mar 2020
Sanofi 10% owner
Sold, plan not stated
$63.12M 128,914 at 489.65
0.6%
24 Feb 2020
YANCOPOULOS GEORGE President and Chief Scientific
Sold, plan not stated
$49.63M 118,123 at 420.17
18.6%
13 Dec 2019
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 7×
$19.49M 51,842 at 376.04
14.5%
10 Sep 2019
Sanofi 10% owner
Sold, plan not stated
$48.61M 172,904 at 281.15
0.8%
8 Mar 2019
Sanofi 10% owner
Sold, plan not stated
$54.04M 131,115 at 412.17
0.6%
6 Sep 2018
Sanofi 10% owner · indirect
Sold, plan not stated
$42.52M 104,552 at 406.68
0.4%
10 Jul 2018
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 8×
$27.42M 74,670 at 367.22
15.7%
21 Jun 2018
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 13×
$24.50M 74,710 at 327.87
15.7%
8 Jun 2018
Sanofi 10% owner · indirect
Sold, plan not stated
$37.61M 121,601 at 309.31
0.5%
25 Aug 2017
Sanofi 10% owner · indirect
Bought 9×
$34.84M 72,378 at 481.36
0.3%
First buy on file
24 Aug 2017
Sanofi 10% owner · indirect
Bought 14×
$51.01M 105,820 at 482.04
0.4%
First buy on file
23 Aug 2017
Sanofi 10% owner · indirect
Bought 5×
$29.02M 60,595 at 478.98
0.3%
First buy on file
22 Aug 2017
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 14×
$15.26M 31,944 at 477.64
8.8%
21 Aug 2017
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 3×
$11.41M 24,269 at 470.32
6.3%
2 Jun 2017
Sanofi 10% owner · indirect
Bought 15×
$65.06M 136,050 at 478.17
0.6%
First buy on file
11 Jan 2017
Sanofi 10% owner · indirect
Bought 18×
$32.27M 87,298 at 369.71
0.4%
First buy on file
Showing 1–48 of 48.